Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has appointed Moncef Slaoui, PhD, to its ...

Agreement grants Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet ...

Enhancing its peptide synthesis capabilities to meet increasing demand from its global partners for efficient and scalable ...

Harbour BioMed, a global biopharmaceutical company, and Sichuan Kelun Biotech BioPharmaceutical have entered into a license ...

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its ...

Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, has appointed Lori ...

Veeda Group has unveiled a new logo and brand identity— Veeda Lifesciences —reflecting the brand’s evolution from a ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.